Gemcitabine combinations may leads to lower overall survival ‐ Gemcitabine plus other combinations of chemotherapy compared with gemcitabine alone (low certainty).
Combination leads to higher smoking cessation compared with single‐form nicotine replacement therapy (high certainty).
Combination showed no clear difference in overall serious adverse events compared with single‐form nicotine replacement therapy (low certainty).
It is very uncertain whether combination changes treatment withdrawals compared with single‐form nicotine replacement therapy (very low certainty).
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).
Combination showed no clear difference in treatment‐related death compared with single‐agent chemotherapy (moderate certainty).
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).
MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).
It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).
It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).
It is very uncertain whether combination therapy changes total mortality compared with monotherapy (very low certainty).
It is very uncertain whether combination therapy changes cardiovascular events compared with monotherapy (very low certainty).
It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).
It is very uncertain whether combination therapy changes withdrawals due to adverse effects compared with monotherapy (very low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.